The NHS has Elephants and Eagles8 Aug 2021 21:29
I should start by repeating what may have said here already and thank Seaboy for sharing his intelligent knowledge with us.
The NHS has elephants and eagles. The elephants focus diligently on not making simple mistakes, being very disciplined and empathic to patient care. The eagles do this, but have the additional academic resource or simply incredibly talented people that lead their particular disciplines and are referred as the eagles. To give folks some idea the NHS employs over 40,000 engineers and scientists in the workforce and they cover over 40 separate disciplines. Professor Holgate and many of the Synairgen team will know who the eagles are in many of these disciplines and will have quite extensive contacts in various Royal Colleges, Department of Health, Research Councils, NHS patient representative groups, the charities (AMRC) and the NHS management structure and other parts of the system. Synairgen was created through the Biobanks infrastructure some 17/18 years ago through Southampton University via the Welcome Trust/MRC/Department of Health initiatives. Professor Newton who was was on television during number 10 briefings in the first Covid-19 wave was part of the group that created those Biobanks and Chaired many of those early meetings. Additionally, Southampton University ran the Health Technology Assessment (HTA) research programme for the Department of Health for decades which evaluates new technologies that are available and influences what should be taken up in the NHS as best practice. Although HTA it may not cover medicines, the MHRA has responsibility for both medicines and health medical device technologies and so the systems do overlap and resources internally do talk to each other. An area of overlap for example was in phamacogenetics.
The upshot of all this, is that I would not be surprised if some hospitals in the NHS have not heard of Synairgen offering as a therapeutic to Covid-19. The health economic uptake models used by Department of Health England usually show the NHS response on highly effective medications and health technologies take around 3 years to be universally adopted. The eagle hospitals take up the proved new developments first usually succeeding a 30% take up rate in year one. By end of year 2, it usually hits 70% and the remainder, usually under financial and skill resource stress are late responders. The pandemic itself will slow transmission of communications and experts seeing one another to influence change. Overall, press attention may speed uptake and one of the challenges for the company is to gauge production supply with uptake models by National Health agencies.
Finally the Synairgen chart is running at the top of its resistance line at 160p. The long term support line is at 128p. The 1 October target price is 146p. The share has stayed between resistance and support for weeks. Nothing to suggest 1 October deadline has changed.
Tony
Sign In
Follow the stocks
